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Summary
INTRODUCTION: The aim of this study was to assess the
clinical outcomes of high-risk patients with severe aortic
stenosis (AS) allocated to medical treatment (MT), tran-
scatheter aortic valve replacement (TAVR), and surgical
aortic valve replacement (SAVR) through extended follow-
up.
METHODS AND RESULTS: Consecutive patients with se-
vere symptomatic AS included in a prospective single cen-
tre registry underwent sweep follow-up between March
and August 2016. Clinical outcomes were assessed using
a competing risk model. A total of 442 patients (median
age 83 years; 52% female) were allocated to MT (n =
78), SAVR (n = 107), or TAVR (n = 257) with a gradient
of surgical risk as assessed by logistic EuroSCORE (MT:
27.9 ± 14.5%, TAVR: 24.7 ± 24.9%, SAVR: 12.5 ± 8.2%;
p <0.001). Survival after a median duration of follow-up of
seven years was 6.4% (MT), 30.4% (TAVR), and 46.7%
(SAVR), respectively (p <0.001). One TAVR and one
SAVR patient underwent repeat intervention for valvular
degeneration between 4.5 and 8.4 years after intervention.
Compromised left ventricular function (LVEF <40%) was
associated with increased mortality (HR 1.62, 95% CI
1.22–2.15; p <0.0001), whereas female sex was protec-
tive (HR 0.68, 95% CI 0.53–0.88; p = 0.0006).
CONCLUSION: Both TAVR and SAVR reduced mortality
compared to MT throughout a median duration of follow-
up of seven years. Repeat interventions for valvular de-
generation were rare.
Keywords: aortic valve stenosis, TAVR, SAVR, medical
treatment, outcome
Introduction
As the most commonly acquired valvular heart disease
with a prevalence of up to 4.6% in patients older than 75
years, aortic stenosis (AS) carries a high short-term mor-
tality once patients become symptomatic [1]. Surgical aor-
tic valve replacement (SAVR) could significantly reduce
mortality in patients with symptomatic severe AS who are
more than 60 years of age. However, for patients deemed
to be a high surgical risk, transcatheter aortic valve re-
placement (TAVR) has been proven to be the preferred
valuable therapeutic option with a significant growth since
its introduction in 2002. Randomised controlled trials
show an absolute reduction of mortality of more than 20%
in inoperable patients at five years (TAVR versus medical
treatment (MT)), as well as comparable five-year mortality
rates for TAVR compared with SAVR [2, 3]. Extended fol-
low-up comparing the three treatment strategies is scarce
yet important in view of the uncertainty regarding the long-
term durability of bioprostheses. The aim of this study
was to assess long-term clinical outcomes of patients at in-
creased risk with symptomatic, severe AS allocated to MT,
SAVR, and TAVR through extended follow-up over five
years. Preliminary results have been previously published
as a conference abstract [4].
Methods
Consecutive patients aged ≥80 years with severe sympto-
matic AS (echocardiographic mean gradient >40 mm Hg
or calculated aortic valve area <1 cm2) and the presence
of a logistic EuroSCORE of >15% included in a prospec-
tive single centre registry between July 2007 and Septem-
ber 2010 underwent follow-up between March and August
2016. Criteria for inclusion and definitions have been re-
ported previously [5]. Of note, patients <80 years of age
were eligible in the case of a previous history of cardiac
surgery, chronic obstructive pulmonary disease (forced ex-
piratory volume during one second <1.0), severe pul-
monary hypertension (≥60 mmHg), porcelain aorta, history
of radiation therapy to the mediastinum, or frailty (BMI
<18 kg/m2).
All subjects provided written informed consent and the
study was approved by the local ethics committee. Reasons
for treatment allocation were based upon anatomical and
technical considerations, estimated periprocedural risk,
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and patient preference as well as a consensus decision
within the local heart team. A considerable proportion of
patients allocated to MT (48.7%) were only at intermediate
surgical risk but refused to undergo SAVR or TAVR, de-
spite the recommendation of the heart team. The selection
process (multimodal assessment during a short hospitali-
sation) included left and right heart catheterisation, aor-
tography, transthoracic and transoesophageal echocardio-
graphy, and CT angiography of the chest, abdomen, and
pelvis. Subspecialty assessment was requested for comor-
bidities such as malignancies, chronic pulmonary disease,
renal failure, liver cirrhosis, and bleeding diathesis. All
eligible cases were discussed within the local heart team
and a consensus decision was then presented and discussed
with the patient. MT consisted of treatment of cardiac and
non-cardiac comorbidities according to best clinical prac-
tice. Balloon aortic valvuloplasty was not offered as part
of the MT strategy, nor as a bridge to SAVR in patients
with congestive heart failure. SAVR and TAVR were per-
formed according to contemporary standards. TAVR in-
cluded the use of either the Edwards Sapien valve or the
Medtronic CoreValve Revalving system through a trans-
femoral, transapical, or trans-subclavian approach using
standard techniques. We assessed clinical outcomes as time
to first event using Cox regression, accompanied by log-
rank tests to calculate corresponding two-sided p-values.
We performed a sensitivity analysis by including the logis-
tic EuroSCORE as an additional covariate to derive adjust-
ed hazard ratios. Moreover, we analysed all-cause mortali-
ty using a competing risk model, with MI and major stroke
as competing events. Patients were considered to be simul-
taneously at risk for all three mutually exclusive events and
were no longer at risk for the other events if one of the
events occurred [6]. We tested for equality across groups
using the subdistribution hazard for each cause of failure
[7]. Analyses were performed using Stata release 14.2 and
R version 3.3.2. We used the Stata stcox function to as-
sess the clinical outcomes and the sts test function to eval-
uate equality of survivor functions [8]. For the competing
risk model, we used the cuminc function included in the R
package cmprsk [9]. In patients with a repeat intervention,
follow-up data after the repeat procedure were not included
in any further analysis. All suspected events were adjudi-
cated by an unblinded clinical event committee consisting
of cardiac surgeons and interventional cardiologists.
Results
A total of 442 patients (median age 83 years; 52% female)
were allocated to MT (n = 78), SAVR (n = 107), or TAVR
(n = 257) after evaluation by the heart team, reflecting
a gradient of surgical risk as assessed by logistic Eu-
roSCORE (MT: 27.9 ± 14.5%, TAVR: 24.7 ± 24.9%,
SAVR: 12.5 ± 8.2%; p <0.001). Baseline clinical and imag-
ing characteristics are outlined in table 1. The delay be-
tween the evaluation visit and the treatment (SAVR or
TAVR) averaged 37 ± 46 days (median 27 days) and was
mainly due to a delay of the final patient decision. Of
note, ten patients died during the time period between ini-
tial evaluation and definitive treatment. Nonetheless, 11
of the 78 MT patients (14%) were reassessed and crossed
over to TAVR (n = 9) or SAVR (n = 2) after a median of
two years (range 25–1159 days). Of note, seven patients of
the MT group changed their mind and agreed to undergo
TAVR (n = 6) or SAVR (n = 1). Procedural data and out-
comes have been reported previously [5]. In summary,
rates of major adverse cerebro-cardiovascular events were
lower in the SAVR or TAVR cohort as compared with
MT patients (SAVR vs. MT: HR 0.31, 95% CI 0.21–0.46;
TAVR vs. MT: HR 0.34, 95% CI 0.25–0.46), with no sig-
nificant difference between SAVR and TAVR (HR 0.88,
95% CI 0.62–1.25) after a median duration of follow-up of
3.9 years. Although SAVR (HR 0.39, 95% CI 0.24–0.61),
TAVR (HR 0.37, 95% CI 0.26–0.52), and female sex (HR
0.72, 95% CI 0.53–0.99) were associated with improved
survival, body mass index ≤20 kg/m2 (HR 1.60, 95% CI
1.04–2.47), diabetes (HR 1.48, 95% CI 1.03–2.12), pe-
ripheral vascular disease (HR 2.01, 95% CI 1.44–2.81),
atrial fibrillation (HR 1.74, 95% CI 1.28–2.37), and pul-
monary hypertension (HR 1.43, 95% CI 1.03–2.00) were
previously identified as independent predictors of mortal-
ity [10]. Regarding the current analysis, completeness of
follow-up was 99.1%. Echocardiographic data are illustrat-
ed in table 2. At or beyond five years, the difference (mean
± standard deviation) in left ventricular ejection fraction
(LVEF, %) was still statistically significant (SAVR 58 ±
12, TAVR 56 ± 13, MT 44 ± 13; p <0.001). However, al-
most all patients of the MT cohort and almost half of the
TAVR patients had died in between. Consistent follow-up
echocardiography was poorer in SAVR patients (47%) as
compared with TAVR patients (93%). The postinterven-
tional mean gradient in both SAVR and TAVR patients
did not significantly change over time. In an intention-to-
treat analysis, survival after a median duration of follow-
up of seven years was 6.4%, 30.4%, and 46.7% in pa-
tients with MT, TAVR, and SAVR, respectively (p <0.001)
(fig. 1). There were no significant differences in the occur-
rence of disabling stroke (5.7%) or myocardial infarction
(2.5%) between the different treatment modalities. Long-
term outcomes are depicted in table 3. Crossover from MT
to SAVR or TAVR occurred in 11 patients (14.1%). One
TAVR patient (0.4%) and one SAVR patient (0.9%) un-
derwent repeat intervention for bioprosthetic valve degen-
eration between 4.5 and 8.4 years after the intervention.
None of the patients experienced a major adverse car-
diovascular event during repeat intervention for biopros-
thetic valve degeneration. Impaired left ventricular func-
tion (LVEF <40%) was associated with increased mortality
(HR 1.62, 95% CI 1.22–2.15; p <0.0001) whereas female
sex was protective (HR 0.68, 95% CI 0.53–0.88; p =
0.0006).
Discussion
In this observational and prospective single centre study,
both TAVR and SAVR were associated with a pronounced
survival benefit. The increasing mortality gap between
TAVR and SAVR patients on the one hand, and a narrow-
ing gap between MT and TAVR patients between five and
seven years on the other, reflect the significantly older age
(median/interquartile range) of patients assigned to MT
(84/7) and TAVR (83/7) as compared to SAVR (80/8) (p
<0.001). Of note, all-cause mortality rates between TAVR
and SAVR patients were comparable within the first year
of intervention despite a surgical risk almost twice as high
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in TAVR as compared to SAVR patients, as assessed by
EuroSCORE. In both treatment modalities, observed mor-
tality was lower than predicted. A high risk of mortality
secondary to comorbidities in combination with lenient in-
Table 1: Baseline characteristics.
Overall
n = 442
MT
n = 78
SAVR
n = 107
TAVR
n = 257
p-value*
Age (yrs) 81.7 ± 6.0 83.2 ± 5.7 79.7 ± 5.5 82.1 ± 6.2 <0.001
Women 230 (52.0%) 33 (42.3%) 53 (49.5%) 144 (56.0%) 0.09
BMI (kg/m2) 25.6 ± 4.6 24.4 ± 3.5 26.0 ± 4.7 25.8 ± 4.9 0.03
Cardiac risk factors
Hypertension 338 (76.5%) 52 (66.7%) 85 (79.4%) 201 (78.2%) 0.08
Current smoker 65 (14.7%) 7 (9.0%) 16 (15.0%) 42 (16.3%) 0.27
Diabetes mellitus 101 (22.9%) 18 (23.1%) 21 (19.6%) 62 (24.1%) 0.65
Hypercholesterolaemia 233 (52.7%) 32 (41.0%) 46 (43.0%) 155 (60.3%) 0.001
Positive family history for coronary artery disease 78 (17.6%) 12 (15.4%) 17 (15.9%) 49 (19.1%) 0.65
Past medical history
Prior MI 79 (17.9%) 23 (29.5%) 9 (8.4%) 47 (18.3%) 0.001
Prior PCI 77 (17.4%) 10 (12.8%) 9 (8.4%) 58 (22.6%) 0.003
CABG 76 (17.2%) 18 (23.1%) 4 (3.7%) 54 (21.0%) <0.001
Previous stroke 44 (10.0%) 13 (16.7%) 8 (7.5%) 23 (8.9%) 0.08
Peripheral vascular disease 93 (21.0%) 16 (20.5%) 13 (12.1%) 64 (24.9%) 0.03
Symptoms
NYHA functional classes
III and IV
251 (56.9) 48 (62.3) 48 (44.9) 155 (60.3) 0.014
Angina 157 (35.5%) 27 (34.6%) 55 (51.4%) 75 (29.2%) <0.001
Syncope 51 (11.5%) 14 (17.9%) 13 (12.1%) 24 (9.3%) 0.11
Cardiac rhythm
Atrial fibrillation 105 (23.8%) 20 (25.6%) 19 (17.8%) 66 (25.7%) 0.25
Prior pacemaker 39 (8.8%) 4 (5.1%) 9 (8.4%) 26 (10.1%) 0.39
Risk assessment (%)
Log. EuroSCORE 22.3 ± 14.6 27.9 ± 14.5 12.5 ± 8.2 24.7 ± 24.9 <0.001
Lin. EuroSCORE 10.2 ± 2.5 11.2 ± 2.2 8.3 ± 2.0 10.7 ± 2.5 <0.001
STS score 6.0 ± 5.0 6.5 ± 4.1 4.8 ± 5.3 6.4 ± 5.0 0.009
Medications
Acetylsalicylic acid 254 (57.5%) 39 (50.0%) 59 (55.1%) 156 (60.7%) 0.21
Clopidogrel 62 (14.0%) 10 (12.8%) 5 (4.7%) 47 (18.3%) 0.003
Oral anticoagulation 114 (25.8%) 22 (28.2%) 18 (16.8%) 74 (28.8%) 0.05
Echocardiography†
LVEF (%) 52 ± 14 46 ± 16 57 ± 12 51 ± 14 <0.001
Mean gradient (mm Hg) 45 ± 17 41 ± 19 52 ± 15 44 ± 17 0.001
AVA (cm2) 0.7 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.82
Invasive PA syst. pressure (mm Hg) 52 ± 18 57 ± 19 43 ± 16 54 ± 17 <0.001
BMI = body mass index; CABG = coronary artery bypass grafting; EuroSCORE = European System for Cardiac Operative Risk Evaluation; Lin. = linear; Log. = logarithmic; MI =
myocardial infarction; LVEF = left ventricular ejection fraction; MT = medical treatment; NYHA = New York Heart Association; PA = pulmonary artery; PCI = percutaneous coronary
intervention; STS = Society of Thoracic Surgeons. Values are n (%) or mean ± standard deviation, unless otherwise indicated. * Continuous variables were compared with analy-
sis of variance and categorical variables with Pearson’s chi-square test. † Transthoracic echocardiography assessment used; if missing, transoesophageal echocardiography
assessment used.
Table 2: Echocardiographic parameters.
Overall
n = 442
MT
n = 78
SAVR
n = 107
TAVR
n = 257
p-value
Baseline
LVEF (%) 52 ± 14 46 ± 16 57 ± 12 51 ± 14 <0.001
Mean gradient (mmHg) 45 ± 17 41 ± 19 52 ± 15 44 ± 17 0.001
AVA (cm2) 0.7 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.82
At 3 years n = 278 n = 7 n = 37 n = 159
LVEF (%) 55 ± 11 44 ± 11 55 ± 9 55 ± 15 <0.001
Mean gradient (mmHg) 10.6 ± 6 47 ± 10 13.1 ± 7 11 ± 4 0.22
AVA (cm2) 1.4 ± 0.6 0.6 ± 0.3 1.4 ± 0.6 1.5 ± 0.6 0.18
At or beyond 5 years n = 142 n = 5 n = 28 n = 109
LVEF (%) 56 ± 13 44 ± 13 58 ± 12 56 ± 13 <0.001
Mean gradient (mmHg) 11.8 ± 5 45 ± 16 12.7 ± 5 10 ± 5 0.14
AVA (cm2) 1.6 ± 0.4 0.5 ± 0.3 1.5 ± 0.4 1.7 ± 0.4 0.27
AVA = aortic valve area; LVEF = left ventricular ejection fraction Values are n (%) or mean ± standard deviation, unless otherwise indicated. Transthoracic echocardiography
assessment used; if missing, transoesophageal echocardiography assessment used.
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vestigation into the causes of death limit the assessment of
valve deterioration during the extended follow-up. Two pa-
tients (1 TAVR, 1 SAVR) underwent repeat intervention for
valvular degeneration; neither experienced a major adverse
Figure 1: Cumulative incidence curves of all-cause death. The competing risk model shows patients allocated to MT (red), TAVR (black), and
SAVR (blue). SAVR vs MT: p <0.0001; TAVI vs MT: p <0.0001. Confidence intervals are depicted as dashed lines.
Table 3: Clinical long-term outcomes.
Overall
n = 442
MT
n = 78
SAVR
n = 107
TAVR
n = 257
SAVR vs MT
HR (95% CI)
p-value TAVR vs MT
HR (95% CI)
p-value
At 1 year
All-cause mortality 112 (25.3) 43 (55.1) 21 (19.6) 48 (18.7) 0.47 (0.25–0.86) 0.0149 0.27 (0.18–0.41) <0.0001
Cardiovascular death 84 (19.6) 42 (54.0) 11 (10.7) 31 (12.4) 0.28 (0.13–0.60) 0.0011 0.18 (0.11–0.28) <0.0001
Myocardial infarction 5 (1.3) 1 (1.3) 0 (0.0) 4 (1.7) * 0.98 (0.11–8.92) 0.9840
Major stroke 18 (4.2) 2 (3.7) 4 (3.8) 12 (4.8) 1.11 (0.15–8.26) 0.9192 1.83 (0.41–8.21) 0.4286
All-cause mortality or major stroke 123 (27.8) 44 (56.4) 23 (21.5) 56 (21.8) 0.48 (0.26–0.87) 0.0154 0.33 (0.22–0.49) <0.0001
All-cause mortality, MI, or major stroke 125 (28.3) 44 (56.4) 23 (21.5) 58 (22.6) 0.48 (0.26–0.87) 0.0151 0.35 (0.23–0.52) <0.0001
At 3 years
All-cause mortality 183 (41.4) 55 (70.5) 33 (30.8) 95 (37.0) 0.51 (0.31–0.86) 0.0121 0.35 (0.25–0.49) <0.0001
Cardiovascular death 132 (31.8) 52 (67.8) 18 (18.3) 62 (26.0) 0.34 (0.18–0.63) 0.0007 0.24 (0.17–0.35) <0.0001
Myocardial infarction 7 (1.9) 2 (4.2) 0 (0.0) 5 (2.3) * 0.53 (0.10–2.80) 0.4538
Major stroke 23 (5.9) 3 (6.8) 8 (8.6) 12 (4.8) 0.87 (0.18–4.11) 0.8592 1.17 (0.33–4.16) 0.8119
All-cause mortality or major stroke 190 (43.0) 56 (71.8) 36 (33.6) 98 (38.1) 0.52 (0.31–0.86) 0.0108 0.38 (0.27–0.53) <0.0001
All-cause mortality, MI, or major stroke 193 (43.7) 57 (73.1) 36 (33.6) 100 (38.9) 0.51 (0.31–0.85) 0.0097 0.38 (0.27–0.52) <0.0001
At 5 years
All-cause mortality 243 (55.3) 66 (84.6) 43 (40.3) 134 (52.7) 0.46 (0.29–0.73) 0.0010 0.36 (0.27–0.49) <0.0001
Cardiovascular death 178 (44.6) 60 (79.8) 29 (30.4) 89 (39.4) 0.37 (0.22–0.64) 0.0003 0.26 (0.19–0.37) <0.0001
Myocardial infarction 9 (2.8) 2 (4.2) 0 (0.0) 7 (3.6) * 0.66 (0.13–3.25) 0.6048
Major stroke 25 (6.8) 3 (6.8) 9 (10.0) 13 (5.5) 0.9 (0.19–4.15) 0.8897 1.21 (0.34–4.27) 0.7710
All-cause mortality or major stroke 251 (57.1) 67 (85.9) 46 (43.1) 138 (54.2) 0.46 (0.29–0.72) 0.0008 0.38 (0.28–0.52) <0.0001
All-cause mortality, MI, or major stroke 254 (57.8) 68 (87.2) 46 (43.1) 140 (55.0) 0.45 (0.29–0.72) 0.0007 0.37 (0.28–0.50) <0.0001
At 7 years
All-cause mortality 299 (73.6) 72 (92.3) 55 (59.3) 172 (73.5) 0.50 (0.33–0.77) 0.0016 0.41 (0.31–0.54) <0.0001
Cardiovascular death 223 (62.5) 65 (88.4) 39 (46.5) 119 (60.7) 0.43 (0.26–0.69) 0.0006 0.31 (0.23–0.42) <0.0001
Myocardial infarction 11 (3.9) 2 (4.2) 0 (0.0) 9 (5.5) * 0.74 (0.15–3.56) 0.7096
Major stroke 25 (6.8) 3 (6.8) 9 (10.0) 13 (5.5) 0.90 (0.19–4.15) 0.8897 1.21 (0.34–4.27) 0.7710
All-cause mortality or major stroke 305 (75.0) 73 (93.6) 57 (60.2) 175 (74.9) 0.48 (0.32–0.74) 0.0008 0.42 (0.32–0.56) <0.0001
All-cause mortality, MI, or major stroke 309 (75.8) 73 (93.6) 57 (60.2) 179 (76.2) 0.48 (0.32–0.74) 0.0008 0.43 (0.32–0.56) <0.0001
Values are n (%) unless otherwise indicated. CI = confidence interval; HR = hazard ratio; MI = myocardial infarction; * = not possible to estimate
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event secondary to the repeat intervention. In the absence
of follow-up extending to the median duration of valve de-
terioration of surgical bioprostheses [11], a robust and sus-
tained mortality reduction of TAVR with early-generation
devices versus MT throughout seven years of follow-up
further inspires confidence in TAVR.
Our study has several limitations. First, data were acquired
at a single centre and results might not be generalisable
to institutions with different referral patterns and collab-
orations between interventional cardiologists and cardiac
surgeons. Second, patients were allocated to the different
treatment strategies in a non-randomised fashion. Howev-
er, we present adjusted analyses to correct for the selec-
tion bias. Furthermore, the analyses provide outcome data
for all treated patients and thus represent the decisions and
outcomes of unselected patients as encountered in routine
clinical practice.
Conclusions
Our study shows that both TAVR and SAVR are associated
with improved survival as compared to MT throughout a
median duration of follow-up of seven years. Moreover, re-
peat interventions for bioprosthetic valve degeneration are
rare.
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